Golvatinib
Golvatinib (E-7050) is an orally active dual inhibitor targeting c-Met and VEGFR-2 tyrosine kinases, showing potential antineoplastic activity by suppressing tumor growth and angiogenesis. It has been investigated in preclinical studies for various cancers, including hepatocellular carcinoma and glioblastoma, in both in vitro and in vivo models.
Product Specifications
CAS Number
928037-13-2
Product Name Alternative
VEGFR, VEGFR2, Vascular endothelial growth factor receptor, E7050, E-7050, E 7050, c-Met/HGFR, cMet/HGFR, c-Met, cMet, inhibit, Golvatinib, Inhibitor, HGFR
Field of Research
Cardiovascular Research, Signal Transduction
Purity
≥95% (May vary between batches)
Solubility
H2O:< 1 mg/mL (insoluble or slightly soluble) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:100 mg/mL (157.81 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (6.31 mM)
Smiles
CN1CCN (CC1) C1CCN (CC1) C (=O) Nc1cc (Oc2ccc (NC (=O) C3 (CC3) C (=O) Nc3ccc (F) cc3) c (F) c2) ccn1
Molecular Formula
C33H37F2N7O4
Molecular Weight
633.69
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog